Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
584.00    -4.00 (-0.68%)
Bid:
585.00
Ask:
588.00
Spread: 3.00 (0.513%)
Market Cap: £508.81m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

AGM and Q1 Interim Management Statement

12 Feb 2021 07:00

RNS Number : 8764O
Victrex PLC
12 February 2021
 
 

 

12 February 2021

Victrex plc - AGM and Q1 Interim Management Statement

'Positive start but variable improvement trend; full year expectations unchanged'

Victrex plc, an innovative world leader in high performance polymer solutions, releases its first quarter (Q1) Interim Management Statement ahead of its Annual General Meeting (AGM) being held today. Q1 covers the period 1 October to 31 December 2020.

Overall, the Group saw a positive start to FY 2021. Although Q1 was slightly ahead of our expectations, performance remains variable by end market. Asia is seeing the most incremental improvement on a geographic basis, with a mixed performance in Europe and the US.

For Q1 as a whole, Group revenue of £68.7m was 1% ahead of the prior year (Q1 2020: £67.7m), with Q1 Group sales volume of 883 tonnes also being 1% ahead of the prior year (Q1 2020 877 tonnes). Since the 1 October 2020, FY 2021 on a year-to-date (YTD) basis is slightly lower than the prior year, reflecting January being robust but lower than the prior year.

End market performance

Across our end-markets, trading saw an incremental improvement from the low point of H2 2020, with Electronics being notably strong as increased homeworking supports demand for a range of smart devices. Performance in Automotive, Medical and Value Added-Resellers was broadly stable compared to the prior year period, with Automotive benefiting from new application growth and some cyclical recovery, and Medical continuing to see a gradual improvement in procedures, largely in Asia. Whilst Energy saw some limited improvement from the low point of H2 2020, performance was lower than the prior year period. Aerospace remains challenging on a short-term basis.

Mega-programmes

As previously communicated, we continue to see little evidence of any material slowdown in our pipeline of 'mega-programmes'. We remain fully focused on delivering specific milestones as we move closer to greater commercialisation.

 

Financial position

Victrex retains a highly cash generative business model, with our cash position improving since the end of FY 2020. Net cash of £84.4m at 31 December 2020 excludes cash ringfenced for our Panjin VYX facility in China, in what will be a year of high capital expenditure totalling up to £50m for the Group.

Brexit, inventory and supply chain

Following the Brexit trade agreement, which took effect from January 1st 2021, the Group has seen no material issues in its supply chain. High service levels are being maintained for customers, with continued tariff free access into the EU.

Whilst our inventory levels remain high, we are on plan to unwind sales inventory through the remainder of FY 2021, which will start to benefit our working capital position.

COVID-19

 

We have sustained our proactive approach to managing the impact of COVID-19 with the safety, health and well-being of Victrex employees being our highest priority. Our COVID contingency plans remain in place and our supply chain has been unaffected, enabling us to continue to meet our customers' needs in full. Our financial position remains strong and the outlook is starting to improve as some signs of recovery emerge in several of our end markets.

 

Outlook

Jakob Sigurdsson, Chief Executive of Victrex, said: "This is a positive start to FY 2021 and we continue to see incremental improvement across several of our end markets.

"Nevertheless, the incremental improvement trend may remain variable and our assumptions are that we will still see a weaker first half overall, compared to H1 2020 which ended strongly. Consequently, at this early stage, our full year expectations are unchanged.

"Our priorities remain the health, safety and well-being of our employees and delivering strong service levels for our customers. With sustainable products and a strong pipeline of growth opportunities, our Polymer & Parts strategy keeps us well positioned for the medium to long-term."

Analyst & investor conference call

A conference call with management will take place this morning, Friday 12th February 2021, at 0830am GMT via +44 (0) 3333 000804 and PIN 24673921#. A replay of the call is also available at +44 (0) 333 300 0819 and PIN 301336320#.

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Corporate Communications +44 (0) 7809 595831

Richard Armitage, Group Finance Director +44 (0) 1253 897700

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

 

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, provide environmental and societal benefit for customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUARURAAUUAUR
Date   Source Headline
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.